ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

4 years ago
Borderline Personality Disorder, vafidemstat, PORTICO trial

Oryzon today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communic...

ORYZON collaborates with the CMT Research Foundation in the US

by Oryzon Genomics

Oryzon announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures f...

ORYZON reports results and corporate update for half-year ending June 30, 2022

by Oryzon Genomics

4 years ago
Iadademstat, Oryzon Genomics, S.A., Vafidemstat

The company has continued to make progress in this first semester in the clinical development of its iadademstat oncology and vafidemstat neurology programs.

ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers

by Oryzon Genomics

4 years ago
ORYZON, U.S. National Cancer Institute, iadademstat, Cooperative Research and Development Agreement (CRADA), LSD1 inhibitor

Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzon’s clinical stage LSD1 inhibitor, iadademstat, in different types of solid an...

ORYZON announces a New Financing through a Convertible Bond Program for a Total amount up to €20 Million over 30 months

by Oryzon Genomics

4 years ago
Oryzon Genomics S.A, Nice & Green

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the entry into a convertible b...

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Small Cell Lung Cancer

by Oryzon Genomics

4 years ago
iadademstat, Small Cell Lung Cancer, epigenetic enzyme LSD1, myeloid leukemia (AML)., SCLC

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s clinical stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer (...

ORYZON awarded EU Seal of Excellence and public financing of 2 M USD to develop iadademstat in Acute Myeloid Leukemia

by Oryzon Genomics

4 years ago
Oryzon Genomics S.A., Acute Myeloid Leukemia (AML), Seal of Excellence, iadademstat

The funding is for Oryzon’s project entitled “Development of new treatments against Acute Myeloid Leukemia (AML) using iadademstat,an epigenetic drug” with a duration of 30 months (January 2022 ...

ORYZON to give updates on corporate progress in June

by Oryzon Genomics

4 years ago
Oryzon Genomics

ORYZON reports results and corporate update for quarter ended March 31, 2022

by Oryzon Genomics

4 years ago
Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

by Oryzon Genomics

4 years ago
Oryzon, Johns Hopkins University, Kabuki Syndrome, Kennedy Krieger Institute

Oryzon Genomics, S.A. a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical coll...

ORYZON to give updates on corporate progress in May

by Oryzon Genomics

4 years ago
Oryzon Genomics

ORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and continues its expansion of US corporate activities

by Oryzon Genomics

4 years ago
Oryzon Genomics

Dr. Faller has over 30 years of clinical hematology/oncology expertise and broad drug development experience in the design and execution of early to registrational clinical programs across oncology an...